You are here: Industry Insights > Market News > Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

water filter

WATER FILTER FOR WATER PURIFIER

DUST BAG

Small dust filter

HUMIDIFIER FILTER

Oil fume adsorption filter

Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment

FirstWordPharmaFebruary 14, 2022

Tag: singapore , Pfizer , Paxlovid

Favorites

Singapore has received its first batch of Pfizer's oral COVID-19 treatment Paxlovid, after authorities last week said they had approved the tablet for COVID-19 in adults at risk for severe disease, reported CNA.

"This is the first oral antiviral medicine approved for treatment of COVID-19 infection in Singapore," noted said health minister Ong Ye Kung.

Paxlovid cut the risk of COVID-19-related hospitalisations or death by 88.9% when given within three days of symptom onset, according to a Health Sciences Authority (HSA) review of clinical data based on an ongoing Pfizer study.

Previous:Celartics Biopharma announces a new generation mRNA vaccine against COVID-19

Next:EdiGene and Neukio enter collaboration to develop next-generation immune cell therapies

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment - PharmaSources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>